Erivedge BCC Approval Buoys Hedgehog Fans, But Pathway Needs Proof In Other Cancers
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA approval of Curis/Genentech’s hedgehog inhibitor Erivedge validates the class, but basal cell carcinoma is only the ante; cancers exploit hedgehog signaling in a variety of ways yet to be elucidated.